A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors
A phase 1/2 trial of Niraparib in advanced solid tumours, run by GlaxoSmithKline, active and no longer recruiting.
Overview
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT06077877 by GlaxoSmithKline, with 42 participants enrolled, started 2023-10-24 and due to reach its primary completion in 2026-06-30. Interventions recorded: GSK4524101 and Niraparib.
Similar pages
not linked directly; found by shared links- TrialA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
- TrialEfficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
- TrialA Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
- TrialA Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.